Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001209191-21-039233
Filing Date
2021-06-09
Accepted
2021-06-09 17:27:11
Documents
1
Period of Report
2021-06-08

Document Format Files

Seq Description Document Type Size
1 FORM 4 SUBMISSION doc4.html 4  
1 FORM 4 SUBMISSION doc4.xml 4 4067
  Complete submission text file 0001209191-21-039233.txt   5489
Mailing Address 805 LAS CIMAS PARKWAY SUITE 100 AUSTIN TX 78746
Business Address 805 LAS CIMAS PARKWAY SUITE 100 AUSTIN TX 78746 (512) 942-2935
Aeglea BioTherapeutics, Inc. (Issuer) CIK: 0001636282 (see all company filings)

EIN.: 464312787 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O LILLY VENTURES FUND I, LLC 115 W. WASHINGTON STREET,STE 1680-SOUTH INDIANAPOLIS IN 46204
Business Address
Shanafelt Armen (Reporting) CIK: 0001656151 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-37722 | Film No.: 211006073